17 unknown, 14 completed, 6 recruiting, 2 active not recruiting. 10 Phase 2, 7 Phase 3, 6 Not applicable, 5 Phase 4, 4 Phase 1.
Follow Immunosuppressive Agents: new trials by email Literature Review of Immunosuppressive Agents trials Research Report on Immunosuppressive Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy Conventional Therapy, Telitacicept - Refractory Chronic Inflammatory Demyelinating Polyneuropathy | Not applicable | Active not recruiting | Sichuan Academy of Medical Sciences | 76 | 2025-09-26 | 2026-05-19 |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis Upadacitinib, corticosteroids and immunosuppressants - Relapsing Polychondritis | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 30 | 2024-11-15 | 2025-03-12 |
| Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders Inebilizumab, oral immunosuppressant - Neuromyelitis Optica Spectrum Disorder | Unknown | Xuanwu Hospital, Beijing | 50 | 2024-07-09 | 2024-09-19 | |
| Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis Adalimumab Biosimilars Injection, Corticosteroid, Immunosuppressive Agents - Uveitis | Not applicable | Completed | Zhongshan Ophthalmic Center, Sun Yat-sen University | 128 | 2024-03-27 | 2026-09-15 |
| Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Relma-cel - Systemic Lupus Erythematosus | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 24 | 2024-03-01 | 2024-03-07 |
| Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System glucocorticoid, immunosuppressants, targeted therapy - Large Vessel Vasculitis | Recruiting | Nanjing Medical University | 150 | 2024-01-01 | 2025-02-13 | |
| Rescue of Nephrons With ALE.F02 (RENAL-F02) ALE.F02, Rituximab, GlucoCorticoid - Glomerulonephritis Rapidly Progressive | Phase 2 | Recruiting | Alentis Therapeutics AG | 80 | 2023-09-07 | 2026-08-14 |
| Thymosin Alpha-1 for irAE Secondary to ICIs Thymosin Alpha1, Immunosuppressant - IrAE | Phase 4 | Unknown | Jun Wang | 40 | 2023-09-01 | 2023-12-20 |
| Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents - Lupus Nephritis, Remission | Phase 3 | Unknown | Nanjing University School of Medicine | 15 | 2023-04-01 | 2023-05-18 |
| Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy Finerenone, RAS inhibitor, Immune Suppressant - Finerenone, IgA Nephropathy | Completed | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 245 | 2022-12-01 | 2024-06-14 | |
| Combined Immunosuppression for Pediatric Crohn's Disease Infliximab and immunosuppressives, Infliximab - Crohn Disease, Infliximab | Phase 4 | Recruiting | Children's Hospital of Fudan University | 128 | 2022-10-10 | 2026-03-19 |
| Efficacy and Safety of Pirfenidone in CTD-ILD Pirfenidone, glucocorticoid and immunosuppressant - Pirfenidone, Connective Tissue Diseases | Phase 4 | Unknown | Qilu Hospital of Shandong University | 120 | 2022-06-22 | 2022-11-30 |
| Immunosuppressants to Postoperative Infection and Death Immunosuppressive Agents - Organ Transplantation, Immunosuppressive Agents | Unknown | Chung Shan Medical University | 20000 | 2021-12-20 | 2023-11-08 | |
| InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease Infliximab subcutaneous, Immunosuppressive Agents - Inflammatory Disease, Disease Crohn | Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 158 | 2021-11-25 | 2024-12-10 |
| Multi-model Image of Immunosuppressive Agents in TAO immunosuppressive agent - Thyroid Associated Ophthalmopathy | Not applicable | Unknown | Sun Yat-sen University | 12 | 2021-10-15 | 2023-04-18 |
| De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal Immunosuppressive - Single Transplant, 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS | Completed | University of Rome Tor Vergata | 92 | 2020-09-01 | 2023-04-11 | |
| Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection Immunosuppressive Agents - Rheumatic Diseases | Completed | Sociedad Argentina de Reumatologia | 2982 | 2020-08-18 | 2023-02-01 | |
| Immunosupressive Treatment in COVID-19 Patients NO-Immunosuppressive, Immunosuppressive, Immunoglubulins - COVID-19 Infection | Unknown | Spanish Network for Research in Infectious Diseases | 500 | 2020-05-01 | 2020-05-12 | |
| Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease Fecal Microbiota Transplantation, Immunosuppressive Agents - Crohn Disease | Not applicable | Recruiting | Tongji Hospital | 50 | 2020-03-22 | 2026-07-10 |
Showing 20 of 41. Sign in to see all of them.
Crohn Disease (4) · Diabetes Mellitus, Type 1 (3) · Uveitis (3) · COVID-19 (2) · Connective Tissue Diseases (2) · Glomerulonephritis, IGA (2) · Leukemia, Myeloid, Acute (2) · Lupus Erythematosus, Systemic (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Dermatomyositis (1) · Diabetes Mellitus (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Alentis Therapeutics AG (1) · AstraZeneca (1) · Bausch & Lomb Incorporated (1) · Beijing 302 Hospital (1) · Brigham and Women's Hospital (1) · Chiesi Farmaceutici S.p.A. (1) · Children's Hospital of Fudan University (1) · Chung Shan Medical University (1) · City of Hope Medical Center (1) · Da, Yuwei, M.D. (1) · Eli Lilly and Company (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Fujian Medical University (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1)
China (19) · United States (8) · Italy (4) · United Kingdom (3) · Argentina (2) · Germany (2) · Spain (2) · Sweden (2) · Australia (1) · Austria (1) · Belarus (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1)
Andrew Posselt, M.D., Ph.D. (1) · Bohdan Pomahac, MD (1) · Carlos Pavesio, MD (1) · Chien-Ying Lee, PhD (1) · Dan Liang (1) · Douglas Jabs, MD, MBA (1) · Dr. G D'Haens, Phd MD (1) · Fouad Kandeel, MD, PhD (1) · Fu-Sheng Wang, PHD (1) · Guillermo Pons-Estel (1) · Helene Alexanderson, PhD, RPT (1) · Janet T Holbrook, PhD, MPH (1) · Jie Wang (1) · John Kempen, MD, PhD (1)
PMID 10231138, PMID 10583235, PMID 16110027, PMID 18468541, PMID 19808924, PMID 19822296, PMID 20079922, PMID 20542125, PMID 20625136, PMID 20930086, PMID 21352202, PMID 21652026, PMID 21840602, PMID 21861971, PMID 22247489, PMID 22320928, PMID 22409563, PMID 22436957, PMID 22871557, PMID 22925653, PMID 23050812, PMID 23163490, PMID 23327199, PMID 23376821, PMID 25115882, PMID 26338095, PMID 26501236, PMID 26798977, PMID 27220348, PMID 27723281, PMID 28394330, PMID 28477440, PMID 29045736, PMID 29195618, PMID 29250743, PMID 29506054, PMID 29901610, PMID 31790472, PMID 31907076, PMID 32817121, PMID 32918964, PMID 34408744, PMID 35870709, PMID 35947992, PMID 36109639, PMID 36201124, PMID 36454054, PMID 38070921, PMID 38299639, PMID 38676311
P30CA036727 (1), U10EY014660 (1)